Century Therapeutics Is Maintained at Overweight by Piper Sandler

Dow JonesDec 31, 2024 01:29 · Ratings

Century Therapeutics Analyst Ratings

BenzingaDec 31, 2024 01:15 · Ratings

Piper Sandler Maintains Century Therapeutics(IPSC.US) With Buy Rating, Cuts Target Price to $4

Futu NewsDec 30, 2024 19:31 · Ratings

Clear Street Launches Healthcare & Biotechnology Equity Research

BusinesswireDec 18, 2024 03:00

Shinobi Strengthens Leadership to Propel Scalable Immune-Evasive Cell Therapies to the Clinic

PR NewswireDec 17, 2024 20:30

Century Therapeutics Faces Termination of BMS Agreement

TipRanksDec 14, 2024 06:27